We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aflac (AFL) to Report Q3 Earnings: Is a Beat in the Cards?
Read MoreHide Full Article
Aflac Incorporated (AFL - Free Report) is scheduled to release third-quarter 2021 results on Oct 27, after the market closes.
Q3 Estimates
The Zacks Consensus Estimate for the company’s earnings per share is pegged at $1.30, indicating a fall of 6.47% from the prior-year quarter’s reported figure. The consensus mark for revenues stands at $5.38 billion, which suggests a decline of 4.97% from the year-ago quarter’s reported number.
Factors to Impact Q3 Results
At Aflac’s Japan segment, revenues are likely to have gained from increased premium, driven by higher sales of its new medical product and improved pandemic conditions compared with the prior-year scenario. At the U.S. segment, sales are likely to have gone up, aided by improved pandemic conditions.
Net investment income is likely to have gone up, primarily on higher variable net investment income.
Expenses are likely to have been high, weighing down the margins. Constant digital investments in its core technological platforms and their upgrades might have flared up costs. However, the company is trying to control costs wherever possible and to this end, it took numerous cost-curbing measures, which might have partially offset the stress on margins.
Earnings Surprise History
The company boasts an impressive earnings surprise history as its bottom line beat estimates in each of the trailing four quarters, the average being 19.92%. This is depicted in the chart below:
What Our Quantitative Model Predicts
The proven Zacks model predicts an earnings beat for Aflac this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here.
Earnings ESP: Aflac has an Earnings ESP of +1.44%. This is because the Most Accurate Estimate of $1.32 is pegged higher than the Zacks Consensus Estimate of $1.30. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Aflac has a Zacks Rank #2, currently.
Other Stocks to Consider
Here are some other stocks worth considering from the insurance space with the perfect mix of elements to surpass estimates in their upcoming releases.
Image: Bigstock
Aflac (AFL) to Report Q3 Earnings: Is a Beat in the Cards?
Aflac Incorporated (AFL - Free Report) is scheduled to release third-quarter 2021 results on Oct 27, after the market closes.
Q3 Estimates
The Zacks Consensus Estimate for the company’s earnings per share is pegged at $1.30, indicating a fall of 6.47% from the prior-year quarter’s reported figure. The consensus mark for revenues stands at $5.38 billion, which suggests a decline of 4.97% from the year-ago quarter’s reported number.
Factors to Impact Q3 Results
At Aflac’s Japan segment, revenues are likely to have gained from increased premium, driven by higher sales of its new medical product and improved pandemic conditions compared with the prior-year scenario.
At the U.S. segment, sales are likely to have gone up, aided by improved pandemic conditions.
Net investment income is likely to have gone up, primarily on higher variable net investment income.
Expenses are likely to have been high, weighing down the margins. Constant digital investments in its core technological platforms and their upgrades might have flared up costs. However, the company is trying to control costs wherever possible and to this end, it took numerous cost-curbing measures, which might have partially offset the stress on margins.
Earnings Surprise History
The company boasts an impressive earnings surprise history as its bottom line beat estimates in each of the trailing four quarters, the average being 19.92%. This is depicted in the chart below:
What Our Quantitative Model Predicts
The proven Zacks model predicts an earnings beat for Aflac this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here.
Earnings ESP: Aflac has an Earnings ESP of +1.44%. This is because the Most Accurate Estimate of $1.32 is pegged higher than the Zacks Consensus Estimate of $1.30. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Aflac has a Zacks Rank #2, currently.
Other Stocks to Consider
Here are some other stocks worth considering from the insurance space with the perfect mix of elements to surpass estimates in their upcoming releases.
Cigna Corp. (CI - Free Report) currently has an Earnings ESP of +2.19% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here..
Athene Holding Ltd. currently has an Earnings ESP of +1.71% and is a Zacks #2 Ranked stock.
MetLife, Inc. (MET - Free Report) currently has an Earnings ESP of +1.21% and is a Zacks #3 Ranked stock.